The authors regret that data related to dietary supplement use in current chemotherapy users was originally omitted from Table 2. The correct Table 2 is included below:
Table 2.
Association between participant characteristics and vitamin/mineral (VM) or non-vitamin/mineral, natural product (NP) supplement use
| Characteristic |
Any VM supplements |
Any non-VM supplements |
||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Age (per 5y) | 1.20 (1.10–1.32) | < 0.001 | 0.99 (0.94–1.05) | 0.847 |
| Time since dx (per y) | 1.01 (0.98–1.04) | 0.600 | 0.98 (0.97–1.00) | 0.117 |
| USA region | ||||
| West | 1.0 (ref.) | 1.0 (ref.) | ||
| South | 0.76 (0.45–1.30) | 0.320 | 0.55 (0.39–0.78) | < 0.001 |
| Midwest | 0.74 (0.40–1.35) | 0.322 | 0.71 (0.47–1.08) | 0.109 |
| Northeast | 0.91 (0.47–1.75) | 0.773 | 0.50 (0.33–0.76) | 0.001 |
| Race | ||||
| Caucasian | 1.0 (ref.) | 1.0 (ref.) | ||
| African American | 0.47 (0.25–0.92) | 0.026 | 0.56 (0.34–0.93) | 0.025 |
| Native American | 0.32 (0.08–1.19) | 0.088 | 0.45 (0.14–1.41) | 0.171 |
| Asian/Pacific Islander | 0.84 (0.19–3.72) | 0.823 | 1.58 (0.52–4.83) | 0.423 |
| Other | 0.54 (0.27–1.09) | 0.086 | 0.75 (0.44–1.27) | 0.280 |
| Ethnicity | ||||
| Not Hispanic/Latina | 1.0 (ref.) | 1.0 (ref.) | ||
| Hispanic/Latina | 0.99 (0.44–2.20) | 0.971 | 0.84 (0.50–1.40) | 0.502 |
| HR+ | ||||
| Negative | 1.0 (ref.) | 1.0 (ref.) | ||
| Positive | 2.50 (1.66–3.76) | < 0.001 | 1.53 (1.14–2.05) | 0.005 |
| HER2+ | ||||
| Negative | 1.0 (ref.) | 1.0 (ref.) | ||
| Positive | 0.71 (0.43–1.15) | 0.163 | 0.87 (0.63–1.21) | 0.421 |
| Chemotherapy (ever) | ||||
| No | 1.0 (ref.) | 1.0 (ref.) | ||
| Yes | 0.71 (0.48–1.04) | 0.078 | 0.91 (0.71–1.15) | 0.425 |
| Current chemotherapy | ||||
| No | 1.0 (ref.) | 1.0 (ref.) | ||
| Yes | 0.42 (0.27–0.65) | < 0.001 | 0.75 (0.54–1.04) | 0.086 |
| Endocrine therapy (ever) | ||||
| No | 1.0 (ref.) | 1.0 (ref.) | ||
| Yes | 2.90 (1.97–4.27) | < 0.001 | 1.44 (1.12–1.85) | 0.004 |
| Current endocrine therapy | ||||
| No | 1.0 (ref.) | 1.0 (ref.) | ||
| Yes | 2.60 (1.75–3.86) | < 0.001 | 1.25 (0.99–1.59) | 0.066 |
| Radiation (ever) | ||||
| No | 1.0 (ref.) | 1.0 (ref.) | ||
| Yes | 1.08 (0.74–1.57) | 0.706 | 0.92 (0.72–1.17) | 0.481 |
| Current radiation | ||||
| No | 1.0 (ref.) | 1.0 (ref.) | ||
| Yes | 0.48 (0.27–0.86) | 0.013 | 0.87 (0.56–1.38) | 0.564 |
| Advanced disease | ||||
| No | 1.0 (ref.) | 1.0 (ref.) | ||
| Yes | 1.35 (0.77–2.37) | 0.296 | 1.06 (0.76–1.48) | 0.731 |
HER2+, human epidermal growth factor receptor 2-positive; HR+, hormone receptor-positive.
The authors would like to apologise for any inconvenience caused.